A Clinical Trial of P134 Cells in Recurrent Glioblastoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Clinical Trial of P134 Cells in Recurrent Glioblastoma — Stella

Recruiting

Back to Recurrent Glioblastoma IDH Wildtype trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Beijing Tiantan Hospital, Capital Medical University, Beijing

Key details

Phase

Early testing / Safety & dosing

Sponsor

Tasly Pharmaceutical Group Co., Ltd

Enrollment target

~26 participants

Started

January 2026

Primary completion

February 2028

Age range

18 Years – 70 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov